

Stem Cell Reports, Volume 17

Supplemental Information

Upregulation of β -catenin due to loss of miR-139 contributes to motor neuron death in amyotrophic lateral sclerosis

Sophie Hawkins, Seema C. Namboori, Ammarah Tariq, Catherine Blaker, Christine Flaxman, Nidhi S. Dey, Peter Henley, Andrew Randall, Alessandro Rosa, Lawrence W. Stanton, and Akshay Bhinge

Figure S1






Figure S1. Related to figures 1 and 2.

A) Representative images of healthy (80a and 79a) MNs and FUS ALS (FUS H517Q/H517Q and FUS H517Q/+) at day 45. Scale bar indicates 100µm. **B**). Hierarchical cluster analysis of 844 miRNAs in FUS H517Q/H517Q, FUS H517Q/+ and healthy MNs. N = 2 independent differentiations.


Figure S2

A



★ Indicates potential direct target of miR-139

B



C





Figure S2. Related to figure 3.

A) Schematic of activated and inhibited canonical WNT signalling (left and right panels respectively). Canonical WNT signalling is activated by the binding of WNT ligands to frizzled and LRP5/6 co-receptors on the cell surface. This leads to the recruitment and sequestration of the β -catenin destruction complex to the membrane, preventing further phosphorylation and ubiquitin-mediated destruction. β -catenin accumulates and translocates to the nucleus where it binds to TCF and promotes transcription of downstream target genes. Image created with Biorender. Stars indicate the top three potential direct targets of miR-139 displayed in Fig.3E. **B)** Representative images of in-cell western blots in figure 3F. The circles indicate the area used for quantification. **C)** RT-qPCR analysis of CTNNB1 / β -catenin transcript in Day 34 FUS H517Q/H517Q MNs in response to miR-139 overexpression. N = 3 independent differentiations. Error bars indicate SEM. * indicates p-value < 0.05.


Figure S3

A

Isogenic




P525L



ISL1 MAP2 TUJ1 Nuclear

B

MN efficiency for P525Ls



C




Figure S3: Related to figure 4

A) Representative images: Isogenic and P525L MNs immunostained with ISL1, MAP2 and TUJ1. Scale bar indicates 300uM. **B)** MN differentiation efficiency, determined by ISL-1+ nuclei. N = 3 independent differentiations. **C)** Representative images for in-cell western blot. Left panel = FUS H517Q/H517Q vs healthy MNs (80A). Right panel = FUS P525L vs isogenic control MNs. Circles indicate area used for quantification.

Figure S4




Figure S4: Related to figure 4, role of WNT in FUS ALS MN degeneration

A) Quantification of ISL1 positive FUS H517Q/H517Q MN at day 45 relative to day 30 after treatment with small molecule inhibitors of the indicated pathways. Horizontal dotted line indicates MN loss in the DMSO only control. N = 3 independent differentiations. **B)** Quantitative RT-qPCR indicating upregulation of CTNNB1 transcript 48 hours post-transduction in healthy (80A) MN progenitors. N = 3. N indicates the number of independent differentiations. * indicates p-value < 0.05, ** indicates p-value < 0.01. P-values were estimated by Student's two-tailed t-test.

Figure S5




Figure S5. Schematic depicting shRNA design for miR-139-5p overexpression

Antibody	Species	Brand / identifier	Dilution
ISL-1	Ms / Rb	Abcam ab86501 / ab108517	1:500
NF-H	Rb	Sigma N4142	1:1000
MAP2	Ms / Rb	Abcam ab11267 / ab32454	1:1000
TUJ1	Ck	Abcam ab107216	1:1000
Total β -catenin	Rb	Abcam ab16051	1:500 1:4000
Non-phospho β -catenin	Rb	CST 8814	1:500
Tubulin	Ms	Abcam ab7291	1:1000

Table S1. Primary antibodies used for immunofluorescence and western blot

Target	Forward 5' to 3'	Reverse 5' to 3'
AXIN2	G TGAGGTCCACGGAACTGT	TGGCTGGTGCAAAGACATAG
DKK1	CCTTGGATGGGTATTCCAGA	CCTGAGGCACAGTCTGATGA
CCND3	TTGCACATGATTTCTGGCC	ACTTCAGTGCCAGTGATCCC
WNT3	CGCACGACTATCCTGGAC	GAGGCGCTGTCATACTTGTC
WNT4	CTAGCCCCGACTTCTGTGAG	TTGGACGTCTTGTTGCATGT
WNT5B	CGGGAGCGAGAGAAGAACT	CGTCTGCCATCTTATACACAGC
WNT10B	GATACCCACAACCGCAATTC	GGGTCTCGCTCACAGAAGTC
WNT11	GGCCAAGTTTTCCGATGCTC	CACCCCATGGCACTTACACT
CTNNB1	CACAAGCAGAGTGCTGAAGGTG	GATTCCTGAGAGTCCAAAGACAG
HPRT1	CATTATGCTGAGGATTTGGAAAGG	CTTGAGCACACAGAGGGCTACA
RPL13	CCTGGAGGAGAAGAGGAAAGAGA	TTGAGGACCTCTGTGTATTTGTCAA

Table S2. Primer sequences for mRNA qPCR

Target	5' to 3'
Universal R	GCATAGACCTGAATGGCGGTA
hsa-miR-139-5p	CAGTGCACGTGTCTCCAGTAAAA
SNORD44	GCAAATGCTGACTGAACATGAA
SNORD48	CTCTGAGTGTGTCGCTGATGC
RNU19	GGAATGACTCCTGTGGAGTTGA

Table S3. Primer sequences for microRNA qPCR

Chemical	Source	Pathway / Target
Pifithrin- α hydrobromide	Tocris	TP53
SB203580	Tocris	p38/MAPK
FR180204	SCBT	ERK 1,2
SP600125	SCBT	JNK 1,2,3
XAV 939	Tocris	WNT
AT7519	Selleckchem	CDK1,2,3,4,6,9

Table S4. Small molecule inhibitors

Supplemental experimental procedures

Human iPSC culture

ALS patient-derived FUS H517Q/H517Q iPSC (ND35663), and healthy iPSCs (GM23280A, GM23279A) were obtained from the Coriell Institute for Medical Research. FUS H517Q/H517Q iPSCs were genome edited using CRISPR to generate the FUS H517Q/+ heterozygous cell line. All iPSC lines were maintained as colonies on human ES qualified Matrigel (Corning) in StemFlex (StemCell Technologies). Colonies were routinely passaged in a 1:6 split using EDTA. Mycoplasma testing was conducted regularly to rule out contamination of cultures.

Differentiation of iPSC into spinal motor neurons

iPSC were plated as colonies onto Matrigel and differentiated by treatment with neuronal differentiation media (DMEM/F12:Neurobasal in a 1:1 ratio, HEPES 10mM, N2 supplement 1%, B27 supplement 1%, L-glutamine 1%, ascorbic acid 5uM, insulin 20ug/ml) supplemented with SB431542 (40uM), CHIR9921 (3uM) and LDN8312 (0.2uM) from day 0 till day 4. Cells were caudalized by treatment with 0.1uM retinoic acid starting at day 2 and ventralized with 1uM purmorphamine starting at day 4 and continued till day 8. At day 8, motor neuron progenitors were re-plated onto poly-D-lysine/laminin coated wells and differentiation was induced by treating the cells with N2B27 media supplemented with retinoic acid, purmorphamine and DAPT 10uM. DAPT treatment was stopped at day 13 and media was changed to N2B27 supplemented with BDNF 10ng/ml, GDNF 10ng/ml. Next day (day 14) neuronal cultures were pulsed with mitomycin at a dose of 10ug/ml for 1 hour to prevent further proliferation of any undifferentiated progenitors. Neuronal cultures were maintained by changing half the media every 2-3 days.

Intracellular Ca²⁺ imaging

Day 30 MNs were plated onto poly-D-lysine and laminin coated cover slips that had been sterilized by autoclaving. Cells were loaded with the Ca²⁺ sensitive dye Fura2-AM at a final concentration of 4µg/mL for 60 min at 37°C in a HEPES-buffered saline solution (HBSS) consisting of (140mM NaCl, 3mM KCl, 2mM CaCl₂, 1mM MgCl₂, 2.5mM Glucose, 10mM HEPES-NaOH, pH 7.35).

Coverslips were placed in a chamber on the stage of an inverted microscope (Nikon, 11 Eclipse TE2000-S). The cells were imaged (20x magnification) whilst constantly being perfused with HBSS (~1.4 mL/min). Every 5 seconds, Fura-2 was excited in succession at wavelengths of 340 and 380 nm using a high speed wavelength switcher (Lambda DG-4); the emitted fluorescence images at 510 nm were collected using a CCD camera (Hamamatsu Photonics). After a baseline period, neurons were treated for 2 min with 50µM glutamate dissolved the perfusing HBSS solution. The timeseries of the emission ratio from 340 and 380 excitation, which is proportion to intracellular Ca²⁺, was calculated as described previously (Telezhkin *et al*, 2016). Data was collected in Volocity software (PerkinElmer) and plotted in Origin Pro.

Immunostaining

Cells were fixed with 4% paraformaldehyde, permeabilized with ice-cold methanol for 5 minutes and washed with PBS containing 10% serum for 1 hour at room temperature. Cells were incubated with primary antibodies (Table S1) diluted into PBS containing 1% BSA and incubated overnight at 4°C. Next day, cells were washed and incubated with Alexa-fluor conjugated secondary antibodies (Molecular probes) for 45 minutes at room temperature and nuclei were stained with Hoechst 33542 (Molecular probes). Images were obtained in an automated fashion on the ImageXpress Pico (Molecular devices). Nuclear identification and ISL1 nuclear signal was quantified in an automated fashion using ImageXpress software. Threshold intensities were maintained the same across wells.

MN survival assay

Motor neuron progenitors were plated in 96-well optically clear black tissue culture plates (Greiner). Day 30 cultures were fixed and stained for ISL1 to assess MN counts. A separate plate cultured under the same condition was allowed to proceed till day 45, when it was fixed and stained for ISL1. Nuclei were stained using Hoechst 33342. MN counts at day 45 were compared with day 30 to assess MN survival. We performed three independent differentiations with two technical wells used per replicate. Data from the technical wells was pooled to generate counts for each replicate. Apoptotic cells at day 37 were detected using the CellEvent Caspase 3/7 green detection reagent (Thermofisher) according to manufacturer's instructions. Drug treatments (Table S4) were initiated at day 30 and MN survival performed as described above.

Quantitative RT-PCR

Total RNA was extracted with the miRNeasy kit (Qiagen) or Monarch Total RNA miniprep (NEB) and reverse transcribed using random hexamers and the High Capacity reverse transcription system from Applied Biosystems. Quantitative PCR was performed using the SYBR GREEN PCR Master Mix from Applied Biosystems. The target gene mRNA expression was normalized to the expression of two housekeeping genes (HPRT1 and RPL13), and relative mRNA fold changes were calculated by the $\Delta\Delta C_t$ method. Primer sequences are included in Table S2.

Western blot analysis

Cell lysates were prepared in RIPA buffer, separated on 12% SDS-PAGE gels and proteins were transferred onto PVDF membranes. Membranes were blocked with 5% milk in TBST (25 mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween-20) and probed with corresponding primary antibodies against specific proteins (Table S1). Dylight 680 and 800 secondary antibodies

(Cell signalling technology) were used to detect primary antibodies and proteins were visualized by using fluorescence (Licor).

In-cell western assay

Cells were fixed with 4% paraformaldehyde, permeabilized with ice-cold methanol for 5 minutes and washed with PBS containing 10% serum for 1 hour at room temperature. Cells were incubated with primary antibodies (Table S1) diluted into PBS containing 1% BSA and incubated overnight at 4°C. Next day, cells were washed and incubated with Dylight 680 and 800 secondary antibodies (Cell signalling technology) for 1 hr at room temperature. Fluorescence was captured with the Odyssey CLx Imaging System (LI-COR) according to the manufacturer's instructions.

MicroRNA RT-qPCR

Total RNA was reverse transcribed using the qScript microRNA cDNA Synthesis Kit (QuantaBio). Quantitative PCR was performed with SYBR GREEN PCR Master Mix from Applied Biosystems and fold changes were calculated by the $\Delta\Delta C_t$ method. Primer sequences are included in Table S3.

Caspase 3/7 Assay

Caspase was measured using the Promega Caspase-Glo® 3/7 Assay System kit (G8090). Caspase luminescence is presented relative to cell titer, as measured by Promega CellTiter-Glo® 2.0 Cell Viability Assay.

FUS Knockdown

300,000 SH-SY5Y or MN progenitor cells were nucleofected with 30 pmol silencer select siRNA (Thermo Fisher) against FUS or appropriate scrambled control using the P3 Primary nucleofector kit (Lonza).

RNA sequencing and analysis

RNA was extracted from day 30 neuronal cultures as described above. MicroRNA sequencing libraries were generated from 500ng of RNA using the NEBnext Small RNA kit (NEB) according to manufacturer's instructions and sequenced on an Illumina MiSeq instrument. Raw reads were trimmed to remove adapter sequences, and PCR duplicates collapsed using the fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/index.html). Processed reads were mapped to the microRNA hairpin sequences obtained from miRbase using bowtie (Langmead *et al*, 2009) and custom scripts were used to generate counts per microRNA.

Total RNA extracted as described above was used to generate Illumina libraries for whole transcriptome analysis using the NEBNext Ultra II kit (NEB). RNA-sequencing reads were trimmed using cutadapt (Martin, 2011) and mapped to the human genome hg19 using bwa (Li & Durbin, 2009). Only reads mapping to unique locations were retained for further analysis. For the miRNA OE analysis, total RNA was extracted at day 35. RNA was processed using the Quant-seq kit (Lexogen) to generate 3'end libraries compatible with Illumina. Reads were trimmed using cutadapt and mapped to the hg19 using STAR (Dobin *et al*, 2013).

The DESeq2 R package (Love *et al*, 2014) and custom R scripts were used to analyze the read counts and generate a list of differentially expressed genes sorted by the statistical score. Gene set enrichment analysis was performed using the GSEA software (<http://software.broadinstitute.org/gsea/index>).

Pri-miRNA quantification

We sought to determine pri-miRNA transcript levels from RNA-seq data. Over 60% of all mapped miRNAs to date are intragenic, residing within introns of host genes (Hinske *et al*, 2017). Since most intragenic miRNAs display correlated expression with their host genes (Liu

et al, 2018), we decided to use the host gene expression as a proxy for pri-miRNA expression levels. Standard RNA-seq experiments generate reads that can be classified as intronic or exonic based on whether they map to introns or exons respectively. Since introns are absent in cytosolic mRNAs, RNA-Seq reads mapping to introns can be used to represent levels of unspliced transcripts present in the nucleus. Changes in intronic read counts can be used to measure changes in transcriptional output for a given gene across experimental conditions (Gaidatzis *et al*, 2015). Hence, we measured intronic reads mapping to host genes as estimates of pri-miRNA transcription.

Intronic miRNAs were identified from the miRIAD intragenic microRNA database (Hinske *et al*, 2014). MiRNAs and host genes were shortlisted to those that were expressed in our MN datasets. Custom R scripts were used to quantify reads mapping to intronic regions of host genes from whole transcriptome libraries. Reads were normalised using scale factors generated with DESeq2.

References

- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M & Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29: 15–21
- Gaidatzis D, Burger L, Florescu M & Stadler MB (2015) Analysis of intronic and exonic reads in RNA-seq data characterizes transcriptional and post-transcriptional regulation. *Nat Biotechnol* 33: 722–729
- Hinske LC, Dos Santos FRC, Ohara DT, Ohno-Machado L, Kreth S & Galante PAF (2017) MiRIAD update: using alternative polyadenylation, protein interaction network analysis and additional species to enhance exploration of the role of intragenic miRNAs and their host genes. *Database* 2017
- Hinske LC, França GS, Torres HAM, Ohara DT, Lopes-Ramos CM, Heyn J, Reis LFL, Ohno-Machado L, Kreth S & Galante PAF (2014) miRIAD-integrating microRNA inter- and intragenic data. *Database* 2014
- Langmead B, Trapnell C, Pop M & Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10: R25
- Li H & Durbin R (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25: 1754–1760
- Liu B, Shyr Y, Cai J & Liu Q (2018) Interplay between miRNAs and host genes and their role

in cancer. *Brief Funct Genomics* 18: 255–266

Love MI, Huber W & Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15: 550

Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal* 17: 10–12

Telezhkin V, Schnell C, Yarova P, Yung S, Cope E, Hughes A, Thompson BA, Sanders P, Geater C, Hancock JM, *et al* (2016) Forced cell cycle exit and modulation of GABAA, CREB, and GSK3 β signaling promote functional maturation of induced pluripotent stem cell-derived neurons. *Am J Physiol Cell Physiol* 310: C520–41